Rexin G
Identification
- Name
- Rexin G
- Accession Number
- DB16450
- Description
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Gene Therapies
Other gene therapies - Synonyms
- DeltaRex-G
- DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor
- Mx-dnG1 retroviral vector
- retroviral expression vector bearing anti-cyclin G1 gene construct
- Rexin-G
- External IDs
- Mx-dnG1
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
- Not Available
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
Rexin G is a non-pathogenic entity that mimics SARS-COV2 by binding to receptors to gain entry into human cells. It is being investigated for preventing SARSCOV-2 viral entry, and also acts as an inhibitor of the cyclin G1 pathway.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 1023923-93-4
References
- General References
- Al-Shihabi A, Chawla SP, Hall FL, Gordon EM: Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy. Mol Ther Oncolytics. 2018 Dec 12;11:122-126. doi: 10.1016/j.omto.2018.11.002. eCollection 2018 Dec 21. [PubMed:30581985]
- External Link [Link]
- External Link [Link]
- External Links
- Wikipedia
- Rexin_G
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Not Yet Recruiting Treatment Acute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / Cytokine Storm 1 Not Available Available Not Available Chondrosarcomas / Chordomas / Malignant Neoplasm of Pancreas / MPNST (Malignant Peripheral Nerve Sheath Tumor) / Sarcoma, Osteogenic / Sarcomas / Soft Tissue Sarcoma (STS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on January 21, 2021 01:43 / Updated on February 13, 2021 10:53